(CercleFinance.com) – Valneva announces new positive results in adolescents from the pivotal phase 3 study of its single-dose chikungunya virus (CHIKV) vaccine, results from the most recent analysis evaluating the safety and immunogenicity at six months.
The day 180 results confirmed the previously announced positive initial data and should allow Valneva to submit an application to expand the use of the Ixchiq vaccine in adolescents aged 13 to 17 years.
“These results should also allow the approval of the vaccine in Brazil, which would then constitute the first marketing authorization for use in an endemic population,” adds the company.